Use of Antihistamines in Ocular Therapy

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 16, 3 Issues, 2017

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Use of Antihistamines in Ocular Therapy

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 4(5): 481-483.

Author(s): Acun Gezer.

Affiliation: Istanbul University, Medical Faculty of Istanbul, Department of Ophthalmology, 34750 Capa - Istanbul,Turkey.


Approximately 20% of the general population have allergic symptoms of various forms. One third of these people have also ocular symptoms. Some forms of ocular allergy can cause severe symptoms and result in significant ocular morbidity. Allergic ocular disease consists of allergic conjunctivitis (including seasonal hay fever and perennial allergic rhinoconjunctivitis and acute anaphylaxis), giant papillary conjunctivitis (including vernalis, atopic keratoconjunctivitis and contact lens induced conjunctivitis), contact dermatokeratoconjunctivitis and microbioallergic disease. Histamine is the most prominent mediator in allergic ocular disease and causes increased vasopermeability, vasodilation, and bronchoconstriction, mediated through histamine receptors. Both H1 and H2 receptors have been identified on the ocular surface. Oral H1-receptor blockers can be given to relieve symptoms in the allergic ocular disease, but side effects such as sedation and systemic anticholinergic reactions are possible. Newer oral antihistamines such as astemizole and terfenadine supposedly have lesser side effects. Topical H1-receptor blocking antihistamine drugs are now available. Levocabastine is an agent with proven efficacy. There are no topical H2-receptor antagonists presently available for ocular use, but such agents have theoretic potential, especially in combination with an H1-receptor blocker


ocular allergic disease, hay fever, allergic conjunctivitis, seasonal conjunctivitis, vernal conjunctivitis, atopic conjunctivitis, antihistamine, h receptor antagonist.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 4
Issue Number: 5
First Page: 481
Last Page: 483
Page Count: 3
DOI: 10.2174/156801405774330439
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science